SYNGENE INTERNATIONAL share price has plunged 6% and is presently trading at Rs 830.0.
Meanwhile, the BSE HEALTHCARE index is at 41,279.6 (up 0.9%).
Among the top losers in the BSE HEALTHCARE index today are FDC (down 3.4%) and GLAND PHARMA (down 1.3%).
HIKAL CHEMIC (up 3.2%) and SUVEN PHARMACEUTICALS (up 2.3%) are among the top gainers today.
Over the last one year, SYNGENE INTERNATIONAL has moved down from Rs 837.9 to Rs 830.0, registering a loss of Rs 7.9 (down 0.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 41,279.6, registering a gain of 45.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 113.6%), GSK Pharma (up 107.4%) and SUVEN PHARMACEUTICALS (up 106.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,984.2 (up 1.4%).
The top gainers among the BSE Sensex today are Ultratech Cement (up 2.2%) and M&M (up 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,386.9 (up 1.1%). Eicher Motor and ONGC are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 79,984.2, registering a gain of 14,030.8 points (up 21.3%).
SYNGENE INTERNATIONAL net profit fell 19.0% YoY to Rs 757 million for the quarter ended June 2024, compared to a profit of Rs 934 million a year ago. Net sales declined 2.3% to Rs 7,897 million during the period as against Rs 8,081 million in April-June 2023.
For the year ended March 2024, SYNGENE INTERNATIONAL reported 9.8% increase in net profit to Rs 5,100 million compared to net profit of Rs 4,644 million during FY23. Revenue of the company grew 9.3% to Rs 34,886 million during FY24.
The current Price to earnings ratio of SYNGENE INTERNATIONAL, based on rolling 12 month earnings, stands at 67.9.
Equitymaster requests your view! Post a comment on "SYNGENE INTERNATIONAL Plunges 6%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!